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Abstract
Background: Atrial fibrillation (AF) is often paroxysmal and minimally symptomatic, hindering its diagnosis. Smartwatches
may enhance AF care by facilitating long-term, noninvasive monitoring.
Objective: This study aimed to examine the accuracy and usability of arrhythmia discrimination using a smartwatch.
Methods: A total of 40 adults presenting to a cardiology clinic wore a smartwatch and Holter monitor and performed scripted
movements to simulate activities of daily living (ADLs). Participants’ clinical and sociodemographic characteristics were abstracted
from medical records. Participants completed a questionnaire assessing different domains of the device’s usability. Pulse recordings
were analyzed blindly using a real-time realizable algorithm and compared with gold-standard Holter monitoring.
Results: The average age of participants was 71 (SD 8) years; most participants had AF risk factors and 23% (9/39) were in
AF. About half of the participants owned smartphones, but none owned smartwatches. Participants wore the smartwatch for 42
(SD 14) min while generating motion noise to simulate ADLs. The algorithm determined 53 of the 314 30-second noise-free
pulse segments as consistent with AF. Compared with the gold standard, the algorithm demonstrated excellent sensitivity (98.2%),
specificity (98.1%), and accuracy (98.1%) for identifying irregular pulse. Two-thirds of participants considered the smartwatch
highly usable. Younger age and prior cardioversion were associated with greater overall comfort and comfort with data privacy
with using a smartwatch for rhythm monitoring, respectively.
Conclusions: A real-time realizable algorithm analyzing smartwatch pulse recordings demonstrated high accuracy for identifying
pulse irregularities among older participants. Despite advanced age, lack of smartwatch familiarity, and high burden of comorbidities,
participants found the smartwatch to be highly acceptable.
(JMIR Cardio 2019;3(1):e13850)  doi: 10.2196/13850
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Introduction
Background
Atrial fibrillation (AF) is the most common heart rhythm
problem in the world and the number of patients living with AF
is increasing rapidly [1,2]. The arrhythmia confers a 3-fold
higher risk for heart failure, a 2-fold risk for dementia, and a
5-fold risk of ischemic stroke among affected individuals,
irrespective of the symptom severity or pattern [1,3]. The
diagnosis of AF often represents a clinical challenge, especially
in its early stages, owing to its paroxysmal and sometimes
asymptomatic nature. Despite the fact that short-lived episodes
may elude clinical surveillance, brief or infrequent episodes of
AF remain associated with higher risk for stroke and death [4,5].
Treatment of AF with oral anticoagulation drastically reduces
the risk for stroke by up to 70% [6], but many patients escape
detection until after a serious complication. For example, 1 in
5 AF patients present with stroke as their first manifestation of
the arrhythmia [7]. New methods for monitoring and screening
are needed to facilitate early AF diagnosis, initiate treatment,
and reduce suffering and death from the arrhythmia.
Systematic and opportunistic screening of older populations for
AF using mobile and digital health is feasible and can identify
asymptomatic, community-dwelling individuals with
undiagnosed AF [8]. Recent European Society of Cardiology
AF guidelines emphasize the importance of opportunistic
screening but stop short of recommending systematic screening
for all individuals, in part owing to the expensive and sometimes
cumbersome nature of the existing rhythm monitoring strategies
[9]. There is considerable interest, however, from AF patients
and families, AF patient advocacy groups, health care providers,
insurers, and health systems to develop lower-cost, more
user-friendly solutions for long-term heart rhythm monitoring
using mobile health (mHealth) devices to empower patients and
reduce suffering from AF [10-12]. The Apple Watch Series 4
recently received Food and Drug Administration (FDA)
clearance for its mobile electrocardiogram (ECG) function that
has been validated in AF patients (data yet unpublished at the
time of writing) [13], marking a monumental milestone in
smartwatch AF monitoring and other mobile technology
developers are likely to follow suit in the near future.
Professional organizations such as the American Heart
Association (AHA) have also shown great enthusiasm and
support for these ventures, and the current AHA president Dr
Ivor Benjamin has claimed that smartwatches that “capture data
[...] in real time [are] changing the way we practice medicine”
[14]. We and other groups have developed accurate automated,
real-time realizable, pulse-based approaches for AF detection
using a smartphone, but this approach, as with ECG-based
approaches using devices that pair with smartphones (ie,
AliveCor Kardia [15]), require that a participant perform an
active rhythm check [10,11]. As prior studies have demonstrated
that even minutes of AF confer risk for ischemic stroke [16],
and as smartwatches can perform passive, frequent pulse
assessments over long periods of time [17,18], there is
considerable interest in adapting existing pulse-based approaches
for use on a smartwatch [17,19,20].
Although appealing, the use of a smartwatch for AF monitoring
introduces unique and significant technical challenges, such as
motion and noise artifacts generated during activities of daily
living (ADLs), as well as usability concerns, as individuals at
risk for AF tend to be older, less familiar with mHealth devices,
and frequently affected by physical and cognitive impairments
that can impede operation of, and comfort with, mHealth
technologies [21].
Objectives
In this investigation, we sought to test the performance of a
novel, real-time realizable, automated algorithm for AF
discrimination using pulse data obtained from a smartwatch
among older individuals with, or at risk for, AF while they
executed simulated ADLs. Furthermore, we assessed study
participants’ impressions of the smartwatch, generally and across
specific usability domains. Finally, we identified characteristics
associated with comfort using a smartwatch for rhythm analysis.
Methods
Design and Setting
This observational study was designed to evaluate the
performance and usability of a smartwatch for heart rhythm
analysis among older individuals with, or at high risk for, AF.
Participants were enrolled between June 2016 and November
2017 from the ambulatory clinics at the University of
Massachusetts Medical Center. All participants provided written
informed consent before the study participation. This study was
approved by the University of Massachusetts Medical School
(UMMS) Institutional Review Board (UMMS IRB number
H00009953).
Study Population
Study staff reviewed the electronic health records (EHR) of all
patients presenting for an ambulatory visit. To be considered
eligible for enrollment, participants were required to be 21 years
of age or older, capable of and willing to provide informed
consent, and able to speak and read English. Individuals were
excluded from study participation if they were pregnant,
incarcerated, had reported an adverse reaction to ECG electrodes
or a Holter monitor, or refused to adhere to any aspect of the
proposed study protocol, including a brief walk test. The staff
telephoned potentially eligible study participants (both those
with and without AF) 1 to 2 weeks before their clinic visit to
assess interest in study participation. A total of 78 patients were
telephoned and 48 patients expressed interest in the study. These
patients were then approached for consent after their clinic visit.
However, 7 patients declined participation at this time and 1
patient was excluded due to wrist size being too large for the
smartwatch, resulting in a final sample of 40 participants.
Trained staff abstracted clinical, electrocardiographic, and
laboratory data from the EHR on all participants, including data
JMIR Cardio 2019 | vol. 3 | iss. 1 | e13850 | p. 2http://cardio.jmir.org/2019/1/e13850/
(page number not for citation purposes)
Ding et alJMIR CARDIO
XSL•FO
RenderX
obtained during the ambulatory visit immediately preceding the
study examination. Resting heart rate and rhythm status, as well
as vital signs, including respiratory rate, systolic and diastolic
blood pressure, and body mass index, were obtained on all
participants. The use of cardiovascular medications was also
abstracted from the EHR. The wrist circumference and skin
tone of the participants were determined by the research staff
at the time of their study examination as these factors may
potentially influence pulse recordings obtained by the
smartwatch.
Study Procedures to Simulate Activities of Daily Living
After providing a brief overview of the smartwatch (Samsung
Simband 2, Figure 1) and the study protocol, the trained staff
helped the participants to don the smartwatch and wear the
7-lead Holter monitor (Rozinn RZ153+ Series, Rozinn
Electronics Inc). After ensuring that the watch and Holter
monitor were properly fitted and actively recording, participants
were asked to sit still for 2 min, followed by a 2-min slow walk
(2 miles per hour) down the clinic hallway, followed by a
30-second standing period. The study participants were then
instructed to walk quickly (4 miles per hour) down the clinic
hallway for 2 min, followed by, in sequence, a 1-min stand, a
1-min period of vertical watch-arm movements, a 1-min period
of watch-arm wrist movements, and a 30-second period of
standing still [22]. Participants were then asked to sit and stand
repeatedly from a chair over a 1-min period. Participants were
then asked to climb and descend stairs over a 2-min period,
followed by a 1-min period where participants sat and performed
deep breathing exercises [23,24]. Slight modifications to the
protocol were made for 3 participants to ensure safety: the first
participant omitted the repeated sit and stand sequence because
of recent knee injury, the second only completed 1 min of
climbing stairs because of exertional dyspnea, and the third
participant declined the stairs climbing portion of the protocol
because of injury from a recent motor vehicle accident.
Participants also wore the watch while completing the
questionnaire.
Signal Acquisition, Transfer, and Blinding Procedures
The Samsung Simband 2 (Figure 1) is a wrist-worn mHealth
device capable of performing continuous real-time monitoring
of biophysical data, providing real-time user feedback and
wireless, secure, and asynchronous signal transfer [25]. When
connected to a secure wireless internet network, the Samsung
Simband 2 passively uploads recorded data to ARTIK Cloud
(Samsung Electronics), a Web-based cloud-based data storage
platform used for research. For this study, Samsung engineers
provided us with access to ARTIK Cloud and technical support.
We generated a study identification number (ID) for each
participant and entered this into the Simband 2 to link
photoplethysmogram (PPG) pulse data to secure study data
(Figure 2). PPG data identifiable only based on study ID was
uploaded to the ARTIK Cloud using a secure connection.
Investigators at the University of Connecticut (UConn) group
who were blinded to the participants’ rhythm status performed
offline rhythm analysis using the real-time realizable algorithm.
Figure 1. Samsung Simband 2 smartwatch showing simultaneous single-lead ECG (electrocardiogram) and PPG (photoplethysmogram) recordings.
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Figure 2. Representative electrocardiographic, pulse, and pulse interval waveforms as recorded by the Samsung Simband 2.0 smartwatch from study
participants in various rhythm states. Panels 1 to 4 (top to bottom) represent patients in various rhythm states: (1) shows a patient in normal sinus rhythm,
(2) shows a patient with premature atrial contractions, (3) shows a patient with premature ventricular contractions, and (4) shows a patient in atrial
fibrillation. For each patient, the single-lead electrocardiogram (a) and pulse plethysmography waveforms (b) are collected by the smartwatch. The
pulse interval (c) and Poincare plots (graphed on right) for each patient are also calculated and represented. BPM: beats per min; HR: heart rate; ECG:
electrocardiogram; PPG: photoplethysmogram.
Motion Noise Detection
Once downloaded onto secure UConn study servers, each
participant’s pulse data were divided into 30-second segments
and then analyzed using a novel motion noise artifact (MNA)
detection algorithm. The details of the MNA detection algorithm
have been described elsewhere [26]. In brief, the MNA
algorithm employs a combination of features derived from a
time-frequency analysis and the significance of the
accelerometer data’s amplitude to determine MNA severity and
a previously derived threshold MNA value is used to determine
whether or not a segment is analyzable [26]. After discarding
MNA-corrupted PPG segments, we calculated features to
classify AF from normal sinus rhythm (NSR).
Pulse Analysis and Rhythm Discrimination
AF is characterized by disorganized atrial electrical activity that
stimulates the ventricles in a random fashion that increases
beat-to-beat variability. Our approach to pulse analysis from
PPG data has been described in detail and uses 2 validated
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statistical techniques. The first of these methods, sample entropy
(SampEn), measures the complexity of pulse variability. The
second, root mean square of successive difference of RR
intervals (RMSSD), quantifies peak-to-peak pulse waveform
variability; the pulse peak determination methodology has also
been previously described [27]. Next, SampEn and RMSSD are
combined into a single parameter (Comb) to discriminate
between AF and normal rhythms. The combined parameter
yields greater area under the receiver operating characteristic
curve than either SampEn or RMSSD. We used the combined
threshold value of Comb=0.94. Moreover, as a second step, a
novel method based on Poincare plot was used to identify
ectopic premature atrial or ventricular contractions (PACs,
PVCs; paper under review and personal communication by DH,
September 2018). Each 30-second segment of PPG data obtained
from the smartwatch was blindly assigned, by the UConn team,
a designation of AF or not AF on the basis of this automated
analysis. We have previously derived and validated thresholds
for detecting PACs/PVCs using a 2-dimensional Poincare plot,
which plots the length of each RR interval against the previous
RR interval to visualize the beat-to-beat variability in these
waveforms among individuals with an irregular pulse [28]. This
graph is used to identify bigeminal, trigeminal, and
quadrigeminal patterns, which are frequently observed patterns
among patients with PACs and PVCs and are common sources
of false positive AF detection [28].
Gold-Standard Electrocardiogram-Based Rhythm
Analysis
A 7-lead Holter monitor was used to record an ECG as the gold
standard for comparison. ECG data from each participant were
labeled with the participant’s study ID and recorded on an
Secure Digital card. Staff downloaded the ECG data and
transferred it securely to UConn investigators (KC, DH, SKB),
where it was stored on firewall protected servers and analyzed
separately from the pulse data from watches. Holter data were
obtained for 41 participants, but were unavailable for 1
participant, likely because of inadequate contact of leads.
The ECG data were divided into 30-second segments and linked
to PPG data using time-stamps and study IDs. Each segment of
ECG data was analyzed by a highly accurate and well validated
AF detection algorithm using a combination of time-varying
coherence functions and Shannon Entropy (ShE) [29] to
establish the rhythm status (gold-standard) for each 30-second
time period. This algorithm is currently used by ScottCare
CardioView Dx, a diagnostic partner program for Holter and
event monitors designed by ScottCare Cardiovascular Solutions.
Similar to the pulse waveforms obtained from the smartwatch,
a subsequent ectopic beat identification algorithm using a
Poincare plot threshold was also applied to the ECG data
windows deemed to have irregular pulse. For quality control,
a board-certified cardiac electrophysiologist (DDM) blinded to
the results of the automated ECG analysis reviewed 10% of the
30-second ECG recordings deemed to be consistent with AF
and 10% of those deemed to be sinus rhythm. Consistent with
prior reports demonstrating excellent performance for AF
detection, there was 100% agreement between clinician and
automated ECG rhythm determinations [29].
Study Questionnaire
We characterized system usability, as well as the psychosocial,
cognitive, and sociodemographic characteristics of study
participants using validated instruments. We also assessed other
factors known to influence perceptions of mHealth devices,
including education level, yearly income, employment status,
and prior experience with smart devices, as measured by
smartphone or smartwatch ownership and social media use.
Usability
Usability in this study was measured globally and across several
usability domains. The Brooke System Usability Scale (SUS)
is a widely used and validated 10-item questionnaire that
assesses multiple dimensions of usability and has been used to
assess prior mHealth devices [30]. Responses to each question
were scored using a standardized 5-point Likert scale
(1=strongly disagree; 5=strongly agree). Responses were
weighted equally and converted to achieve a maximum score
of 100. For reference, a score of ≥68 is consistent with high
usability [30].
A separate investigator-generated assessment was also
administered to measure participants’ perceptions of the
smartwatch’s ease of use, its overall importance, privacy
concerns related to smartwatch use, perceived fit of the device
into daily activities, and comfort with use, as measured by stress
associated with using the device. Participants responded to all
questions using the same 5-point Likert scale used in Brooke
SUS.
Cognitive Impairment and Mood
We employed 3 validated questionnaires to assess cognitive
impairment and mood. The Montreal Cognitive Assessment is
a validated tool for screening of mild cognitive impairment and
is widely used in clinical settings [31]. It includes 30 items and
assesses multiple cognitive domains. The scoring ranges from
0 to 30 and a score <26 is indicative of mild cognitive
impairment. The Patient Health Questionnaire–9 is a validated
9-item instrument for screening, diagnosing, and monitoring
depression in the clinic [32]. A score of 5 to 9 is indicative of
mild, 10 to 14 of moderate, and greater than 15 of severe
depression. The Generalized Anxiety Disorder scale is a
multipurpose 7-item instrument to describe the severity of the
patient’s anxiety symptoms in the past 2 weeks [33]. It is a
well-validated tool used to screen for a variety of anxiety related
disorders, such as generalized anxiety disorder, panic disorder,
and posttraumatic stress disorder. The scores range from 0 to
21, and a score of 5 to 9 is considered mild anxiety, 10 to 14 as
moderate anxiety or related condition, and greater than 15 as
severe anxiety or related condition. This section of the
questionnaire was completed by 22 out of the 40 study
participants.
Data Analysis
We first calculated the proportion of noise-free data segments
out of the total number of data segments. We then calculated
the appropriate test characteristics, including sensitivity,
specificity, and accuracy, to examine the performance of our
automated pulse analysis algorithm from 314 noise-free pulse
segments for the detection of an irregular pulse consistent with
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AF compared with the results of a validated algorithm examining
contemporaneous 7-lead Holter ECG (criterion standard), using
established threshold values of RMSSD, SampEn, and Poincare
plot [10,11].
The overall usability of the smartwatch for arrhythmia
monitoring was examined using validated Brooke SUS.
Unadjusted linear regression was then used to identify
patient-level characteristics associated with overall Brooke SUS
score, as well as Likert-type scores across several usability
domains (system ease of use, system importance to user, system
privacy concerns, perceived fit of system into daily activities,
and comfort with the system, as measured by stress induced by
use). Age, sex, history of coronary artery disease, coronary
bypass graft procedure, cardioversion, stroke, education level,
smartphone ownership, social media use, cognitive impairment,
depression, and anxiety were examined as predictors of these
usability outcomes. All analyses were performed in MATLAB
9.1 (MathWorks) and Stata 13 (StataCorp).
Results
Participant Characteristics
The characteristics of the 40 participants enrolled in the study
are shown in Table 1. The average age of the participants was
71 (SD 8) years, 80% (32/40) were male, and all were
Caucasian. About 1 in 3 participants had a history of coronary
artery disease, 35% (14/40) had undergone a previous
cardioversion, and 23% (9/39) were in AF at the time of their
study visit. Cognitive impairment was common (59%, 13/22),
but symptoms of mild anxiety (18%, 4/22) and depression (18%,
4/22) were less frequently observed. Most participants were
retired (70%, 28/40) and most participants reported an annual
income of US $50,000, Can $67,404.25, Aus $71,560 or more.
Most participants had achieved a high level of education, with
over half having completed college or a graduate degree
program. Although more than half of the participants owned a
smartphone (55%, 22/40), none owned a smartwatch at the time
of the study visit. Participants in AF at the time of their study
visit had, on average, higher heart rates, as well as higher rates
of prior heart failure, cardioversion, anticoagulant use, and
anxiety.
Pulse Rhythm Analysis
A total of 40 participants wore the smartwatch for an average
of 42 (SD 14) min, generating a total of 2538 30-second data
segments of pulse waveform recordings, of which 314 were
noise-free. All data from 1 participant were corrupted by
motion/noise artifact, likely from a poor wristband fit.
Furthermore, 63 out of the 314 clean 30-second pulse segments
were deemed to be irregular/consistent with AF and 251 were
determined to be regular/consistent with normal rhythm. All
windows designated irregular pulse were subsequently subjected
to ectopic beat detection, which correctly salvaged 6 windows
of benign beat irregularities as such compared with ECG data.
Final analysis of the smartwatch-generated pulse segments
resulted in 54 windows deemed AF, 6 windows deemed
PACs/PVCs, and 248 windows deemed NSR. Compared with
the ECG rhythm gold standard, AF was correctly identified
from smartwatch pulse data in 54 out of 55 windows,
corresponding to a sensitivity of 98.2%. The algorithm correctly
identified 254 out of 259 windows as showing either normal
rhythm or PACs/PVCs compared with the reference standard,
corresponding to 98.1% specificity. The pulse analysis algorithm
demonstrated excellent overall accuracy (98.1%) in detecting
the presence of AF. The algorithm had a positive predictive
value of 91.5% and a negative predictive value of 99.6%.
Usability Analysis
All 40 participants were included in the usability analysis. The
smartwatch demonstrated high usability for rhythm analysis,
as determined using the validated Brooke SUS, with over
two-thirds of participants (67.7%) considering the watch to be
highly usable. The average Brooke SUS score was 72.9 (SD
17.5). Individual usability domains, including ease of use,
importance to user, fit into daily activity, comfort with privacy,
and stress associated with use were also assessed using a Likert
scale (1 to 5). These usability domains were generated by the
investigators for the specific purpose of evaluating this
technology and are presented as univariate dot plots to best
represent distribution of responses, which may be more
meaningful than summary statistics. Overall usability was high
across usability domains (Figure 3), with no significant variation
across areas. Unadjusted regression analysis (Table 2) showed
that older age and prior history of coronary artery bypass surgery
were associated with less comfort (as measured by greater
stress), when using the smartwatch for rhythm analysis
(unadjusted beta coefficients −0.039 and −0.935, respectively).
The history of having undergone a cardioversion for AF was
associated with greater comfort with sharing rhythm data using
the smartwatch (unadjusted beta coefficient 0.72).
JMIR Cardio 2019 | vol. 3 | iss. 1 | e13850 | p. 6http://cardio.jmir.org/2019/1/e13850/
(page number not for citation purposes)
Ding et alJMIR CARDIO
XSL•FO
RenderX
Table 1. Baseline characteristics of study participants (N=40).
StatisticsCharacteristics
Demographic characteristics
70.6 (8)Age (years), mean (SD)
32 (80)Sex, male, n (%)
40 (100)Race, Caucasian, n (%)
27 (68)Skin tone: tan
10 (25)Skin tone: pale
3 (8)Skin tone: unspecified
6.9 (0.7)Wrist circumference, inches, mean (SD), (n=32)
Medical characteristics
2.6 (1.3)CHA DS -VASc scorea, mean (SD)
29.3 (5.1)Body mass index, kg/m2, mean (SD)
16.7 (1.2)Respiratory rate, bpmb, mean (SD)
68.8 (14.3)Resting heart rate (per electrocardiogram), bpm, mean (SD)
126.3 (17.7)Systolic blood pressure, mm Hg, mean (SD)
72.0 (10.4)Diastolic blood pressure, mm Hg, mean (SD)
25 (63)Hypertension, n (%)
23 (58)Hyperlipidemia, n (%)
0 (0)Current smoking, n (%)
9 (23)Diabetes mellitus, Type 2, n (%)
13 (33)Coronary artery disease, n (%)
7 (18)Prior coronary artery bypass graft, n (%)
2 (5)Congestive heart failure, n (%)
10 (25)Sleep apnea, n (%)
14 (35)Prior cardioversion (%)
2 (5)Stroke, n (%)
Arrhythmia characteristics, n (%)
28 (70)History of atrial fibrillation
Type of atrial fibrillation
17 (60)Paroxysmal
4 (14)Permanent
5 (18)Persistent
2 (7)Unspecified
Rhythm at time of pulse assessment
30 (77)Sinus rhythm
9 (23)Atrial fibrillation
Treatment characteristics, n (%)
27 (68)Beta-blocker
12 (30)Calcium channel blocker
29 (73)Statin
12 (30)Antiarrhythmic drug
1 (3)Digoxin
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StatisticsCharacteristics
21 (53)Anticoagulant
Psychosocial characteristicsc, n (%)
13 (59)Cognitive impairment
4 (18)Anxiety
4 (18)Depression
Educational status, n (%)
2 (5)Completed some high school
9 (23)Graduated high school
5 (13)Graduated high school, some college
8 (20)Graduated college
2 (5)Graduated college, some graduate school
14 (35)Completed a graduate degree
Employment status, n (%)
7 (17)Employed full-time
4 (10)Employed part-time
1 (3)Full time home-maker or caretaker
28 (70)Retired
Income status, n (%)
1 (4)Less than $10,000
1 (4)$10,000 to $29,999
3 (11)$30,000 to $49,999
3 (11)$50,000 to $69,000
8 (30)$70,000 to $89,999
9 (33)$90,000 to $149,999
2 (7)$150,000 or more
13 (33)Unreported
Technology use, n (%)
22 (55)Own smartphone
0 (0)Own smart watch
aCHA DS -VASc score: clinically used tool for stroke risk assessment.
bbpm: beats per minute.
cCognitive impairment is based on Montreal Cognitive Assessment score <26, anxiety is based on Generalized Anxiety Disorder–7 score >4, and
depression is based on Patient Health Questionnaire–9 score >4. Data are available for 22 participants for all measures.
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Figure 3. Responses to smartwatch for atrial fibrillation usability questions. Each circle represents an individual participant’s coded response.
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Table 2. Factors associated with individual usability domains and system usability score.
Overall Brooke system
usability scoreb
Individual usability domainsVariables
Comfort with
useb
Comfort with
privacyb
Fit into daily
activityb
Importance to
userb
Ease of useb
−0.082
−0.039a0.00−0.02−0.010.02Age
−8.905−0.0630.520.14−0.01−0.38Sex, male
−2.6800.046−0.23−0.190.130.86History of coronary artery diseasec
−2.857
−0.935a0.21−0.26−0.04−0.54Prior coronary artery bypass graftc
0.238−0.0880.72a0.110.15−0.22Prior cardioversionc
11.0420.8420.490.680.271.37Prior strokec
−1.6220.152−0.040.060.020.04Education leveld
−8.2950.468−0.450.210.09−0.07Smartphone ownershipc
−0.8140.030−0.060.03−0.020.37Social media usee
6.656−0.1880.16−0.17−0.19−0.05Cognitive impairmentf
−6.542−0.158−0.610.470.140.37Depressionf
−8.125−0.158−0.610.170.440.21Anxietyf
aIndicates statistical significance at P<.05.
bUnadjusted beta coefficients from univariate regression analysis.
cCoronary artery disease, coronary artery bypass graft, cardioversion, stroke, smartphone ownership are all coded as yes (1) or no (0).
dEducation coded from 1 to 6, from completed some high school to some graduate degree.
eSocial media use coded from 1 to 5, from no use to >6 hours per week.
fCognitive impairment coded as Montreal Cognitive Assessment <26, depression coded as Patient Health Questionnaire–9 >4, anxiety coded as
Generalized Anxiety Disorder−7 >4. Cognitive impairment, depression, and anxiety available for 22 participants.
Discussion
Principal Findings
We enrolled 40 older patients presenting to an ambulatory clinic
in an observational study of mHealth devices for arrhythmia
monitoring. Participants wore a smartwatch (the Samsung
Simband 2.0, Figure 1) for about 40 min and followed a rigorous
protocol to generate motion noise to simulate ADLs. Over 2000
30-second pulse segments were obtained, and after noise
elimination, blinded analysis of over 300 30-second pulse
segments was conducted using a real-time realizable algorithm.
The pulse analysis algorithm demonstrated excellent sensitivity,
specificity, and accuracy for the detection of an irregular pulse
consistent with AF. Despite their advanced age, lack of
familiarity with smartwatches, and high burden of cardiovascular
and noncardiovascular comorbidities, study participants found
the smartwatch highly acceptable overall and across several
important usability domains. We did observe, however, that
younger age and prior history of cardioversion were associated
with greater comfort with use of the device for heart rhythm
monitoring. Our findings demonstrate the accuracy and
acceptability of a real-time realizable pulse-analysis algorithm
analyzing PPG data from a smartwatch among participants at
high risk for incident or recurrent AF.
Current Atrial Fibrillation Detection Modalities
Early AF detection results in treatment with oral anticoagulants
that reduce stroke risk by up to 70% [6], and daily home
monitoring for AF among stroke survivors reduces stroke risk
by ~18% as compared with conventional in-office ECGs when
obtained every 6 to 12 months [34]. In the randomized
COMPAS trial, hospitalizations for atrial arrhythmias and stroke
were higher in conventionally-monitored patients compared
with those prescribed home monitoring, suggesting that home
monitoring for AF has clinical impact and is cost effective [34].
Furthermore, in the STROKESTOP study [8], home monitoring
using intermittent rhythm recordings identified a significant
proportion of previously undiagnosed AF in an older cohort
compared with usual care and has been shown in subsequent
cost-effectiveness analyses to have a favorable quality-adjusted
life years saved [35].
The most commonly prescribed noninvasive ECG monitors
(24-hour Holter monitors) demonstrate low yield for AF
detection across a wide array of high-risk subgroups, likely as
the monitoring coverage of a 24- or 48-hour monitor is simply
too brief [36]. For example, the median time to first AF episode
was approximately 30 days in the Cryptogenic Stroke and
Underlying Atrial Fibrillation study [16,37]. Long-term
implantable monitoring significantly improves paroxysmal AF
detection rates compared with conventional, shorter-term,
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noninvasive monitors, but few patients elect to undergo this
costly and invasive procedure [16].
Owing to the suspected prevalence and adverse health impact
of undiagnosed AF, there is interest in developing new mHealth
tools capable of enabling long-term, noninvasive monitoring.
Recently, several companies have developed new software and
hardware needed to harness the ubiquity and usability of
commercial wrist-based wearable devices for AF screening and
monitoring [10,12]. AliveCor (AliveCor Inc) recently released
the KardiaBand, an FDA-approved, commercially available
smartwatch wristband with an embedded ECG electrode
designed to pair with the Apple Watch for AF monitoring [38].
The most recent version of this technology aims to use a
PPG-based pulse irregularity notification feature to prompt the
user to perform an active rhythm check. This is distinct from
AliveCor’s Kardia device and other commercial ECG-based
devices, such as the MyDiagnostick [39] and Zenicor [40]
products, which have no passive monitoring component. A
recent study including 100 participants undergoing a
cardioversion and wearing the AliveCor KardiaBand showed
that, as in our cohort, MNA was common but AF identification
was possible and fairly accurate compared with physician review
on clean ECG segments [41,42]. Another recent study leveraging
the Health eHeart study also demonstrated that an Apple Watch
can also be used to collect pulse signals and discriminate AF
with modest accuracy compared with self-reported AF using a
deep learning neural network approach [19]. This approach has
also been shown to be modestly accurate and is computationally
intensive. Finally, the SmartWATCHes for Detection of Atrial
Fibrillation study, which analyzed pulse data collected from
smartwatches using different parameters of heart rate variability
than this study (normalized RMSSD and ShE) also found that
pulse data can be accurate for AF diagnosis [20]. These
promising results, in conjunction with our own, further highlight
the importance of addressing human factors such as usability
and implementation considerations.
Like the Apple Watch–AliveCor KardiaBand dyad and similar
to the recently FDA-cleared Apple Watch 4, the Samsung
Simband 2.0 records PPG and single-lead ECG signals using
an electrode embedded in the watch (Figure 1). The Samsung
Simband platform offered several advantages, leading to its
selection for use in our investigation. First, unlike Apple,
Samsung provides investigators with unfettered access to a
secure data management system designed for research (ARTIK
Cloud). Second, Samsung allowed for independent development
of open-source apps and data sharing between researchers.
Pulse-Based Atrial Fibrillation Detection
The pulse analysis approach tested in our study demonstrated
high accuracy for the detection of AF using smartwatch pulse
recordings despite the fact that participants were asked to
perform activities intentionally designed to create MNAs
[23,24]. Owing to the intensity of our motion protocols and
vulnerability of wrist-based devices to signal corruption, our
motion noise detection algorithm deemed 88% of the 30-second
pulse segments to be corrupted. Prior investigators have
observed similar rates of motion noise corruption when
analyzing PPG data for heart rate analysis from smartwatches
[43]. The low coverage noted in our study represents a
significant potential limitation of PPG-based technologies for
heart rhythm monitoring, especially during waking hours and
during active periods. This finding highlights the importance
of noise detection and the need for algorithms to filter and
address MNA [44,45], which may contribute to false positives
(owing to noisy segments that are detected as having AF if the
algorithms are not sufficiently robust) or false negatives (owing
to segments that are eliminated because of noise but include
AF if the algorithms are overly restrictive). Despite low rates
of pulse coverage, we anticipate higher coverage rates in natural
environments, especially during sedentary periods and during
sleep [46]. From a diagnostic perspective, although 5 30-second
pulse segments were incorrectly identified by the algorithm as
being consistent with AF, the clinical significance of such brief
episodes is unknown [47]. To date, only episodes lasting 5 min
or more have been associated with risk for ischemic stroke [48].
We anticipate that future approaches using pulse data from a
smartwatch will be tuned to match performance to clinical use
[49], perhaps requiring multiple, sequential 30-second pulse
segments to demonstrate pulse irregularity or confirmation with
ECG, to reduce false positive AF detection and enhance
usefulness.
Our approach to AF detection using a smartwatch involves
passive pulse acquisition and real-time analysis using methods
that are accurate but not computationally demanding [10,27].
Our approach enhances potential acceptability and successful
implementation as it can be feasibly ported into a wide range
of smartwatch devices with different hardware specifications,
and will not to require any external devices.
Device Usability and Acceptability
Consistent with this hypothesis, most participants deemed the
smartwatch system highly usable overall and expressed comfort
with using the system for home heart rhythm monitoring. Our
finding that the majority of participants owned a smartphone
and were willing to use a smartwatch to monitor themselves
debunks the commonly held misconceptions about older
Americans at risk for AF and their facility with mobile devices,
but is entirely consistent with an emerging literature showing
that older Americans are increasing using smart devices and are
open to using wearables for disease prevention and treatment
[21]. Presently, over 85% of Americans over 65 years currently
use mobile phones, a proportion that is increasing [50].
Smartphone use is becoming increasingly common among
seniors (10% increase in the last 3 years) [50], and despite well
recognized usability barriers, such as physical difficulties,
skeptical attitudes, and difficulty learning new technologies,
older users can adopt new technologies [51] and often prefer
smartphones and smartwatches for running mHealth apps to
conventional diagnostic devices, as was observed in our study
(Figure 3) [52]. Our results also highlight the importance of
proper patient and caregiver education when implementing
novel mHealth interventions. Study staff were responsible for
set up and deployment of the devices in each participant, which
likely facilitated their user experience and contributed to the
high perceived usability.
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Although we did not find significant associations between any
participant characteristics and overall smartwatch usability, we
did observe that older age and history of coronary artery bypass
graft surgery were associated with lesser comfort using the
smartwatch for heart rhythm monitoring, consistent with prior
studies [53]. We observed that participants with a history of
prior cardioversion for AF were more comfortable using and
sharing their heart rhythm data using the smartwatch (Table 2).
This finding likely reflects the relative importance of AF
monitoring among patients already affected by the disease and
perhaps helps to identify an ideal early adopter population to
test home use of smartwatches for heart rhythm monitoring.
In contrast to prior investigations, our study focused on
establishing both the accuracy and usability of a scalable
smartwatch-based approach to AF monitoring and screening
among a population of older potential users during active periods
intended to simulate ADLs. Not only will future studies need
to be conducted to examine long-term adherence to
smartwatches for AF monitoring among at-risk populations,
further work to tune the AF detection algorithm for ideal
performance using large, diverse study cohorts will be required.
Our findings suggest, however, that older users, when provided
support in learning to use smartwatches, can use them well, and
that data derived from these devices are of sufficient quality so
as to enable high quality rhythm analysis.
Strengths and Limitations
Our study has several strengths. First, in contrast to most
mHealth studies involving younger participants, our study was
able to enroll older participants at high risk for incident or
recurrent AF. Second, in contrast to other mHealth studies that
examine performance of signal processing algorithms from
ideal state data, we employed a standardized protocol to
introduce motion noise to simulate ADLs [23,24]. Third, we
conducted blinded analysis of pulse data using validated
methods and rigorous quality control [10,11,29]. Finally, despite
the rapid development of new technologies for smartwatch-based
AF monitoring and enthusiasm in the AF community, we are
the first, to our knowledge, to explore usability and acceptability
of smartwatches for cardiac monitoring in the elderly.
Several limitations of our study warrant presentation. Our
sample was enrolled from an ambulatory clinic at a single
tertiary care medical center in central Massachusetts and was
relatively homogenous with regard to race and gender. This
racial and gender homogeneity significantly limits our ability
to generalize these findings to members of other racial groups,
community-dwelling individuals not under the care of a
physician, or among individuals from other geographic areas.
We plan to rectify this and enrich our study population by
targeting a more diverse sample in future data collection.
Furthermore, the sample was highly educated and reported a
relatively high annual income, potentially limiting
generalizability to less well-educated or poorer individuals. In
addition, our sample was older, affected by a moderate to
significant burden of physical and cognitive impairments, and
the penetrance of smart device use was lower than the national
average [50] (55% owned a smartphone), suggesting that our
findings may underestimate the usability of the smartwatch for
rhythm analysis in other groups. Our gold standard used was
also based on a commercial automated algorithm, and although
cardiologist overread performed on 20% of the sample matched
the algorithm completely, manual overread on the remaining
sample was not performed due to feasibility. In addition,
although we intentionally designed study protocols to generate
MNA from activities of normal daily life, we did not assess
accuracy or usability with home use. The device was tested in
a temperature- and light-controlled clinic environment, and
disturbance of these factors, in addition to variables unmeasured
in our study (such as skin turgor and humidity), may affect
performance. Finally, our study population was a convenience
sample enriched for participants with AF, and as such, the
usability data collected may be affected by selection bias. This
inflated AF prevalence also likely resulted in a higher positive
predictive value for AF identification than in real-world settings,
where the AF prevalence is much lower.
Conclusions
A novel, real-time realizable software algorithm analyzing pulse
data from a smartwatch exhibits excellent performance for the
detection of an irregular pulse consistent with AF among older
individuals creating motion noise to simulate ADLs.
Furthermore, the smartwatch system was deemed highly usable
by older participants enrolled in our study, suggesting that
long-term monitoring for AF using wrist-based mHealth devices
holds promise. Future work is needed to assess provider
impressions of the system, to validate findings from our study
in much larger and more diverse cohorts, and examine long-term
adherence to daily home use, as well as in-field accuracy of AF
diagnosis among older individuals at risk for incident or
recurrent AF.
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